The Thorny Question of Early Diagnosis in Lung Cancer: Should the IP-10 Cytokine be Brought to Trial?
IP-10 can potentially be used as a supplemental serum biomarker for early lung cancer diagnosis. This finding calls for additional validation in bigger, multi-center cohorts to define diagnostic thresholds and investigate their incorporation into multi-marker panels.
Authors
- N. M. Nikitina (ORCID: https://orcid.org/0000-0003-3311-3290)
- Marina Sekacheva (ORCID: https://orcid.org/0000-0003-0015-7094)
- М В Прохорова (ORCID: https://orcid.org/0009-0004-8848-0674)
- Solomon Oloche Onoja (ORCID: https://orcid.org/0000-0003-4159-0994)
- Tatiana Alexandrovna Demura
- Angelina V. Zhilenkova (ORCID: https://orcid.org/0000-0002-0060-2197)
- Freddy Elad Essogmo (ORCID: https://orcid.org/0009-0003-0857-5423)
- Yuliya N. Pirogova (ORCID: https://orcid.org/0000-0002-6434-3155)
- Leonid N. Bagmet
- Alexander S. Rusanov
- Precious Tochukwu Nwodo
- Maurelle T. Sikatie
- Yvan Sinclair Ngaha Tchawe
- Abah Moses Owoicho
- Elena Evgeni’evna Shchelokova
Institutions
- Sechenov University (RU)
Publication Details
- Journal
- Current Cancer Drug Targets
- Published
- 2026-01-12
- DOI
- https://doi.org/10.2174/0115680096415381251122002921
- Primary Topic
- Chemokine receptors and signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.00